Literature DB >> 18353947

Comparative neuropathogenesis and neurovirulence of attenuated flaviviruses in nonhuman primates.

Olga A Maximova1, Jerrold M Ward, David M Asher, Marisa St Claire, Brad W Finneyfrock, James M Speicher, Brian R Murphy, Alexander G Pletnev.   

Abstract

Based on previous preclinical evaluation in mice and monkeys, the chimeric TBEV/DEN4Delta30 virus, carrying the prM and E protein genes from a highly virulent Far Eastern strain of tick-borne encephalitis virus (TBEV) on the backbone of a nonneuroinvasive dengue type 4 virus (DEN4), has been identified as a promising live attenuated virus vaccine candidate against disease caused by TBEV. However, prior to use of this vaccine candidate in humans, its neurovirulence in nonhuman primates needed to be evaluated. In the present study, we compared the neuropathogeneses of the chimeric TBEV/DEN4Delta30 virus; Langat virus (LGTV), a former live TBEV vaccine; and yellow fever 17D virus vaccine (YF 17D) in rhesus monkeys inoculated intracerebrally. TBEV/DEN4Delta30 and YF 17D demonstrated remarkably similar spatiotemporal profiles of virus replication and virus-associated histopathology in the central nervous system (CNS) that were high in cerebral hemispheres but progressively decreased toward the spinal cord. In contrast, the neurovirulence of LGTV exhibited the reverse profile, progressing from the site of inoculation toward the cerebellum and spinal cord. Analysis of the spatiotemporal distribution of viral antigens in the CNS of monkeys revealed a prominent neurotropism associated with all three attenuated viruses. Nevertheless, TBEV/DEN4Delta30 virus exhibited higher neurovirulence in monkeys than either LGTV or YF 17D, suggesting insufficient attenuation. These results provide insight into the neuropathogenesis associated with attenuated flaviviruses that may guide the design of safe vaccines.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18353947      PMCID: PMC2395187          DOI: 10.1128/JVI.00172-08

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  45 in total

1.  Comparison of live and inactivated tick-borne encephalitis virus vaccines for safety, immunogenicity and efficacy in rhesus monkeys.

Authors:  Alexander A Rumyantsev; Robert M Chanock; Brian R Murphy; Alexander G Pletnev
Journal:  Vaccine       Date:  2005-08-09       Impact factor: 3.641

2.  IABs scientific workshop on neurovirulence tests for live virus vaccines, January 31-February 1, 2005, Geneva.

Authors: 
Journal:  Biologicals       Date:  2005-10-28       Impact factor: 1.856

3.  Inflammatory response in human tick-borne encephalitis: analysis of postmortem brain tissue.

Authors:  Ellen Gelpi; Matthias Preusser; Ute Laggner; Ferenc Garzuly; Heidemarie Holzmann; Franz Xaver Heinz; Herbert Budka
Journal:  J Neurovirol       Date:  2006-08       Impact factor: 2.643

4.  Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region.

Authors:  A P Durbin; R A Karron; W Sun; D W Vaughn; M J Reynolds; J R Perreault; B Thumar; R Men; C J Lai; W R Elkins; R M Chanock; B R Murphy; S S Whitehead
Journal:  Am J Trop Med Hyg       Date:  2001-11       Impact factor: 2.345

5.  Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: dose-response effectiveness and extended safety testing in rhesus monkeys.

Authors:  T P Monath; I Levenbook; K Soike; Z X Zhang; M Ratterree; K Draper; A D Barrett; R Nichols; R Weltzin; J Arroyo; F Guirakhoo
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

6.  Chimeric West Nile/dengue virus vaccine candidate: preclinical evaluation in mice, geese and monkeys for safety and immunogenicity.

Authors:  Alexander G Pletnev; David E Swayne; Jim Speicher; Alexander A Rumyantsev; Brian R Murphy
Journal:  Vaccine       Date:  2006-06-21       Impact factor: 3.641

7.  Tick-borne Langat/mosquito-borne dengue flavivirus chimera, a candidate live attenuated vaccine for protection against disease caused by members of the tick-borne encephalitis virus complex: evaluation in rhesus monkeys and in mosquitoes.

Authors:  A G Pletnev; M Bray; K A Hanley; J Speicher; R Elkins
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

8.  Infectious cDNA clone of attenuated Langat tick-borne flavivirus (strain E5) and a 3' deletion mutant constructed from it exhibit decreased neuroinvasiveness in immunodeficient mice.

Authors:  A G Pletnev
Journal:  Virology       Date:  2001-04-10       Impact factor: 3.616

9.  Evaluation of the Langat/dengue 4 chimeric virus as a live attenuated tick-borne encephalitis vaccine for safety and immunogenicity in healthy adult volunteers.

Authors:  Peter F Wright; Sharon Ankrah; Susan E Henderson; Anna P Durbin; Jim Speicher; Stephen S Whitehead; Brian R Murphy; Alexander G Pletnev
Journal:  Vaccine       Date:  2008-01-04       Impact factor: 3.641

10.  Neurovirulence properties of recombinant vesicular stomatitis virus vectors in non-human primates.

Authors:  J Erik Johnson; Farooq Nasar; John W Coleman; Roger E Price; Ali Javadian; Kenneth Draper; Margaret Lee; Patricia A Reilly; David K Clarke; R Michael Hendry; Stephen A Udem
Journal:  Virology       Date:  2006-11-13       Impact factor: 3.616

View more
  20 in total

1.  Neuropathogenesis and neurovirulence of live flaviviral vaccines in monkeys.

Authors:  Inessa Levenbook; Ken Draper
Journal:  J Virol       Date:  2009-05       Impact factor: 5.103

2.  Evaluation of St. Louis encephalitis virus/dengue virus type 4 antigenic chimeric viruses in mice and rhesus monkeys.

Authors:  Joseph E Blaney; James Speicher; Christopher T Hanson; Neeraj S Sathe; Stephen S Whitehead; Brian R Murphy; Alexander G Pletnev
Journal:  Vaccine       Date:  2008-06-13       Impact factor: 3.641

3.  The flavivirus dengue induces hypertrophy of white matter astrocytes.

Authors:  Kim M Lee; Kevin B Chiu; Hope A Sansing; Peter J Didier; Andrew A Lackner; Andrew G MacLean
Journal:  J Neurovirol       Date:  2016-06-06       Impact factor: 2.643

Review 4.  Experimental therapies for yellow fever.

Authors:  Justin G Julander
Journal:  Antiviral Res       Date:  2012-12-10       Impact factor: 5.970

5.  The neurovirulence and neuroinvasiveness of chimeric tick-borne encephalitis/dengue virus can be attenuated by introducing defined mutations into the envelope and NS5 protein genes and the 3' non-coding region of the genome.

Authors:  Amber R Engel; Alexander A Rumyantsev; Olga A Maximova; James M Speicher; Brian Heiss; Brian R Murphy; Alexander G Pletnev
Journal:  Virology       Date:  2010-07-01       Impact factor: 3.616

6.  High-throughput automated image analysis of neuroinflammation and neurodegeneration enables quantitative assessment of virus neurovirulence.

Authors:  Olga A Maximova; Brian R Murphy; Alexander G Pletnev
Journal:  Vaccine       Date:  2010-08-03       Impact factor: 3.641

7.  Insertion of microRNA targets into the flavivirus genome alters its highly neurovirulent phenotype.

Authors:  Brian L Heiss; Olga A Maximova; Alexander G Pletnev
Journal:  J Virol       Date:  2010-12-01       Impact factor: 5.103

8.  Single-dose vaccine against tick-borne encephalitis.

Authors:  Alexander A Rumyantsev; Ana P Goncalvez; Maryann Giel-Moloney; John Catalan; Yuxi Liu; Qing-sheng Gao; Jeff Almond; Harry Kleanthous; Konstantin V Pugachev
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-15       Impact factor: 11.205

9.  Chimeric tick-borne encephalitis/dengue virus is attenuated in Ixodes scapularis ticks and Aedes aegypti mosquitoes.

Authors:  Amber R Engel; Dana N Mitzel; Christopher T Hanson; James B Wolfinbarger; Marshall E Bloom; Alexander G Pletnev
Journal:  Vector Borne Zoonotic Dis       Date:  2010-12-13       Impact factor: 2.133

10.  Assurance of neuroattenuation of a live vaccine against West Nile virus: a comprehensive study of neuropathogenesis after infection with chimeric WN/DEN4Δ30 vaccine in comparison to two parental viruses and a surrogate flavivirus reference vaccine.

Authors:  Olga A Maximova; James M Speicher; Jeff R Skinner; Brian R Murphy; Marisa C St Claire; Danny R Ragland; Richard L Herbert; Dan R Pare; Rashida M Moore; Alexander G Pletnev
Journal:  Vaccine       Date:  2014-04-13       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.